Skip to main content

Advertisement

SpringerLink
Log in

What signals are generated by anti-CD20 antibody therapy?

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Immunotherapy with rituximab (a chimeric anti-CD20 monoclonal antibody), alone or in combination with chemotherapy, has improved the treatment outcome of patients with non-Hodgkin’s lymphoma (NHL), but the in vivo mechanisms by which rituximab exerts its effects have not been elucidated. The mechanisms underlying resistance are not known. In addition to the proposed actions mediated by rituximab (such as complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis), rituximab may signal the tumor cells and inhibit constitutively activated survival signaling pathways (Raf-1-MEK1/2-ERK1/2, p38 MAPK, NF-κB, and Akt), resulting in inhibition of cell growth and of selectively anti-apoptotic gene products such as Bcl-2 and Bcl-xL. The inhibition of these anti-apoptotic gene products by rituximab sensitizes drug-resistant tumor cells to apoptosis induced by a variety of cytotoxic chemotherapeutic drugs. Also, rituximab sensitizes NHL cells to apoptosis resulting from upregulation of death receptors, implicating a novel in vivo role of host involvement in rituximab-mediated effects. We have developed rituximab-resistant clones that do not respond to rituximab-mediated cell signaling. The clones exhibited hyperactivated cell survival pathways and overexpression of anti-apoptotic gene products and could not be chemosensitized by rituximab. Inhibitors of the survival signaling pathways reverse drug resistance in both wildtype cells and resistant clones. These findings identify several novel intracellular pathways modifyed by rituximab that sensitize NHL cells to both chemotherapy and immunotherapy, as well as several therapeutic targets whose modifications reverse resistance. These findings have clinical relevance for both prognosis and novel treatment strategies for patients with NHL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hainsworth JD: Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004, 31(1 Suppl 2):17–21. This review describes clinical findings of prolongation of survival or remission in patients with non-Hodgkin’s lymphoma (NHL) with rituximab maintenance therapy. The response rate of patients with untreated, indolent NHL who were first treated with rituximab followed by maintenance treatment improved from 47% after initial treatment to 73% after maintenance treatment.

    Article  PubMed  CAS  Google Scholar 

  2. Coiffier B: First-line treatment of follicular lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Oncol 2005, 3:484–491. This review describes the outcome of patients with NHL who were treated with rituximab alone or in combination with chemotherapy. The combination treatment resulted in a higher complete response rate and longer time to progression than treatment with rituximab alone.

    PubMed  Google Scholar 

  3. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention [review]. Oncogene 2005, 24:2121–2143. This recent review is the first to describe the effect of rituximab treatment on cell signaling and the modification of survival signaling pathways by rituximab in the laboratory. It also describes gene products involved in resistance to chemotherapy and characterizes the mechanism of rituximab resistance.

    Article  PubMed  CAS  Google Scholar 

  4. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435–445.

    PubMed  CAS  Google Scholar 

  5. Kennedy AD, Solga MD, Schuman TA, et al.: An anti- C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 2003, 101:1071–1079.

    Article  PubMed  CAS  Google Scholar 

  6. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000, 48:673–683.

    Article  PubMed  CAS  Google Scholar 

  7. Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177–186.

    Article  PubMed  CAS  Google Scholar 

  8. Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res 2001, 7:709–723.

    PubMed  CAS  Google Scholar 

  9. Li Z, David G, Hung KW, et al.: Cdk5/p35 phosphorylates mSds3 and regulates mSds3-mediated repression of transcription. J Biol Chem 2004, 279:54438–54444.

    Article  PubMed  CAS  Google Scholar 

  10. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ: The biology of CD20 and its potential as a target for mAb therapy [review]. Curr Dir Autoimmun 2005, 8:140–174. This extensive review describes the effect of rituximab treatment on the cell membrane lipid rafts and inhibition of cell signaling. In addition, it provides possible underlying mechanisms of responsiveness and unresponsiveness to rituximab.

    Article  PubMed  CAS  Google Scholar 

  11. Deans JP, Kalt L, Ledbetter JA, et al.: Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995, 270:22632–22638.

    Article  PubMed  CAS  Google Scholar 

  12. Deans JP, Robbins SM, Polyak MJ, Savage JA: Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998, 273:344–348.

    Article  PubMed  CAS  Google Scholar 

  13. Semac I, Palomba C, Kulangara K, et al.: Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003, 63:534–540.

    PubMed  CAS  Google Scholar 

  14. Jazirehi AR, Vega MI, Chatterjee D, et al.: Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin’s lymphoma B cells by Rituximab. Cancer Res 2004, 64:117–126. This study reveals for the first time that rituximab treatment of NHL cell lines inhibits the MEK1/2-ERK1/2 signaling pathways, resulting in inhibition of AP-1 and Bcl-x transcription. These events led to chemosensitization. This study also demonstrates that rituximab treatment resulted in the induction of RKIP expression and participated in the inhibition of the MEK1/2 signaling pathway.

    Article  Google Scholar 

  15. Bezombes C, Grazide S, Garret C, et al.: Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004, 104:1166–1173. This study describes the mechanisms by which rituximab inhibits cell growth and demonstrates a rituximab-induced rapid and transient increase in acid sphingomyelinase activity. This was accompanied by ceramide generation in raft microdomains and resulted in the induction of cyclic-dependent kinase inhibitors involved in cell proliferation.

    Article  PubMed  CAS  Google Scholar 

  16. Deans JP, Li H, Polyak MJ: CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002, 107:176–182.

    Article  PubMed  CAS  Google Scholar 

  17. Borsellino N, Belldegrun A, Bonavida B: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995, 55:4633–4639.

    PubMed  CAS  Google Scholar 

  18. Mizutani Y, Bonavida B, Nio Y, Yoshida O: Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J Urol 1994, 151:1697–1702.

    PubMed  CAS  Google Scholar 

  19. Su L, David M: Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem 2000, 275:12661–12666.

    Article  PubMed  CAS  Google Scholar 

  20. Blay JY, Burdin N, Rousset F, et al.: Serum interleukin-10 in non-Hodgkin’s lymphoma: a prognostic factor. Blood 1993, 82:2169–2174.

    PubMed  CAS  Google Scholar 

  21. Alas S, Ng CP, Bonavida B: Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin’s lymphoma. Clin Cancer Res 2002, 8:836–845.

    PubMed  CAS  Google Scholar 

  22. Vega MI, Huerta-Yepaz S, Garban H, et al.: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004, 23:3530–3540. This study shows that rituximab-induced inhibition of the IL-10-IL-10R loop in 2F7 DL-DCL resulted from inhibition of p38 MAPK and Sp1, which inhibited IL-10 transcription. Thus, rituximab-mediated inhibition of the p38 MAPK/Sp1/IL10-IL-10R/pSTAT3/Bcl-2 pathway was responsible for chemosensitization.

    Article  PubMed  CAS  Google Scholar 

  23. Jazirehi AR, Gan XH, De Vos S, et al.: Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin’s lymphoma B cell lines to paclitaxelinduced apoptosis. Mol Cancer Ther 2003, 2:1183–1193.

    PubMed  CAS  Google Scholar 

  24. Xerri L, Parc P, Brousset P, et al.: Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol 1996, 92:900–906.

    Article  PubMed  CAS  Google Scholar 

  25. Yeung K, Seitz T, Li S, et al.: Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999, 401:173–177.

    Article  PubMed  CAS  Google Scholar 

  26. Yeung K, Janosch P, McFerran B, et al.: Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 2000, 20:3079–3085.

    Article  PubMed  CAS  Google Scholar 

  27. Ghosh S, Karin M: Missing pieces in the NF-kB puzzle [review]. Cell 2002, 109:81–96.

    Article  Google Scholar 

  28. Dixit V, Mak TW: NF-kB signaling. Many roads lead to Madrid. Cell 2002, 111:615–619.

    Article  PubMed  CAS  Google Scholar 

  29. Yeung KC, Rose DW, Dhillon AS, et al.: Raf kinase inhibitor protein interacts with NF-kB-inducing kinase and TAK1 and inhibits NF-kB activation. Mol Cell Biol 2001, 21:7207–7217.

    Article  PubMed  CAS  Google Scholar 

  30. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer [review]. Nat Rev Cancer 2002, 2:489–501.

    Article  PubMed  CAS  Google Scholar 

  31. Suzuki E, Palladino M, Bonavida B: Rituximab sensitizes resistant B-NHL cell lines to proteasome inhibitor NPI-0052-induced apoptosis [abstract]. Proc Amer Assoc Cancer Res 2006, 47:Abstract 5429.

    Google Scholar 

  32. Hongo F, Garban H, Huerta-Yepez S, et al.: Inhibition of the transcription factor yin yang 1 activity by S-nitrosation. Biochem Biophys Res Commun 2005, 336:692–701.

    Article  PubMed  CAS  Google Scholar 

  33. Huerta-Yepez S, Vega M, Jazirehi A, et al.: Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kB and inhibition of Bcl-xl expression. Oncogene 2004, 23:4993–5003.

    Article  PubMed  CAS  Google Scholar 

  34. Garban HJ, Bonavida B: Nitric oxide inhibits the transcription repressor yin-yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 2001, 167:75–81.

    PubMed  CAS  Google Scholar 

  35. Barnhart BC, Alappat EC, Peter ME: The CD95 type I/type II model. Semin Immunol 2003, 15:185–193.

    Article  PubMed  CAS  Google Scholar 

  36. Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B: Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin’s lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005, 175:2174–2183. This study describes for the first time the effect of rituximab-induced upregulation of the death receptor Fas via inhibition of the transcription repressor YY1, resulting in the sensitization of NHL cells to Fas ligand-induced apoptosis. This finding suggests a novel mechanism of rituximab-mediated effect in vivo.

    PubMed  CAS  Google Scholar 

  37. Kennedy AD, Beum PV, Solga MD, et al.: Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004, 172:3280–3288.

    PubMed  CAS  Google Scholar 

  38. Haidar JH, Shamseddine A, Salem Z, et al.: Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Hematol 2003, 70:330–332.

    Article  Google Scholar 

  39. Manshouri T, Do KA, Wang X, et al.: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003, 101:2507–2513.

    Article  PubMed  CAS  Google Scholar 

  40. Jazirehi AR, Bonavida B: Cellular and molecular characterization of rituximab-resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) clones: development of cross-resistance to cytotoxic stimuli [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 3410. This study describes the generation of rituximab-resistant clones as a model to mimic rituximab unresponsiveness in patients. It demonstrates that the resistant clones fail to be triggered by rituximab and cannot be chemosensitized by rituximab. However, the clones can be sensitized by pharmacologic inhibitors of the ERK1/2 and NF-kB pathways.

  41. Jazirehi AR, Bonavida B: Sensitization of rituximab-sensitive and rituximab-resistant B-NHL cell lines/clones to TRAIL-induced apoptosis by bortezomib and NF-kB inhibitors [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1514. This study demonstrates that rituximab treatment of NHL cell lines upregulates the expression of the death receptor DR5 and sensitizes the cells to TRAIL-induced apoptosis. In addition, treatment with bortezomib and NF-kB inhibitors mimics rituximab and sensitizes the cells to TRAIL-induced apoptosis.

  42. Vega M, Jazirehi AR, Bonavida B: New targets identified for therapeutic intervention in the reversal of rituximab and drug resistant AIDS-B-NHL [abstract]. Proc Amer Assoc Cancer Res 2006, 47:Abstract 5424.

  43. Jazirehi AR, Bezombes C, Laurant G, et al.: Characteristics of rituximab-resistant B-NHL clones in lipid raft microdomains and cell signaling [abstract]. Proc Amer Assoc Cancer Res 2006, 47:Abstract 4657.

  44. Alas SA, Bonavida B: Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003, 9:316–326.

    PubMed  CAS  Google Scholar 

  45. Emmanouilides C, Jazirehi A, Bonavida B: Rituximab-mediated sensitization of B-non-Hodgkin’s lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002, 17:621–630.

    Article  PubMed  CAS  Google Scholar 

  46. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B: Rituximab (chimeric anti-CD20 mAb) inhibits the constitutive NIK/IKK/IkB/NF-kB signaling pathway in non-Hodgkin’s lymphoma (NHL) B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005, 65:264–276. This report describes for the first time rituximab-induced inhibition of the NF-kB pathway leading to inhibition of Bcl-x transcription and expression and leading to chemosensitization.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine at UCLA, Jonnson Comprehensive Cancer Center, University of California at Los Angeles, 10833 LeConte Avenue, 90095-1747, Los Angeles, CA, USA

    Benjamin Bonavida PhD

Authors
  1. Benjamin Bonavida PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Bonavida PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonavida, B. What signals are generated by anti-CD20 antibody therapy?. Curr Hematol Malig Rep 1, 205–213 (2006). https://doi.org/10.1007/s11899-006-0001-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-006-0001-z

Keywords

Search

Navigation